INO-5401 + INO-9012 + LIBTAYO Emerging Drug Insight and Market Forecast - 2032

This “INO-5401 + INO-9012 + LIBTAYO Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about INO-5401 + INO-9012 + LIBTAYO for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the INO-5401+ INO-9012 + LIBTAYO for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the INO-5401+ INO-9012 + LIBTAYO for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INO-5401+ INO-9012 + LIBTAYO market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

INO-5401, being developed by Inovio for cancer treatment, is T-cell activating DNA immunotherapy. INO 5401 encodes multiple antigens, including Inovio's SynCon antigens for human telomerase (hTERT), Wilms tumor gene-1 (WT1), and PSMA are prevalent in multiple cancers. Besides, INO-9012 is an investigational DNA-based cancer vaccine developed by the same company. It consists of a DNA molecule (plasmid) that encodes for interleukin-12 (IL-12), which is an inflammatory molecule naturally produced by various immune cells (such as macrophages and dendritic cells) in response to foreign invasion. Currently, the treatment is being studied in combination with other experimental therapies for treating many types of cancers and viral infections.

INO-9012 is administered into the patient's muscle by electroporation, which uses electric shocks to introduce DNA into cells. Upon administration, the patient's cells read the DNA to produce IL-12, which activates the immune system by promoting the growth of specialized immune cells called T cells. T cells then stimulate the production of another cell-signaling molecule called interferon-gamma (IFN-γ), activating other types of immune cells, such as natural killer cells (NK cells) and killer T cells, against tumor cells or virus-infected cells resulting in the inhibition of their growth and their killing. In its annual report 2021, the company mentioned the Phase I/II immuno-oncology trial of INO-5401 and INO-9012 (IL-12 plasmid) in participants with newly diagnosed glioblastoma multiforme (GBM), in combination with cemiplimab developed jointly by Regeneron Pharmaceuticals and Sanofi has been completed.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the INO-5401+ INO-9012 + LIBTAYO description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on INO-5401+ INO-9012 + LIBTAYO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the INO-5401+ INO-9012 + LIBTAYO research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around INO-5401+ INO-9012 + LIBTAYO.
• The report contains forecasted sales of INO-5401+ INO-9012 + LIBTAYO for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for INO-5401+ INO-9012 + LIBTAYO in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INO-5401+ INO-9012 + LIBTAYO Analytical Perspective

In-depth INO-5401+ INO-9012 + LIBTAYO Market Assessment

This report provides a detailed market assessment of INO-5401+ INO-9012 + LIBTAYO for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

INO-5401+ INO-9012 + LIBTAYO Clinical Assessment

The report provides the clinical trials information of INO-5401+ INO-9012 + LIBTAYO for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INO-5401+ INO-9012 + LIBTAYO dominance.
• Other emerging products for GBM are expected to give tough market competition to INO-5401+ INO-9012 + LIBTAYO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INO-5401+ INO-9012 + LIBTAYO in GBM.
• This in-depth analysis of the forecasted sales data of INO-5401+ INO-9012 + LIBTAYO from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INO-5401+ INO-9012 + LIBTAYO in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of INO-5401+ INO-9012 + LIBTAYO?
• What is the clinical trial status of the study related to INO-5401+ INO-9012 + LIBTAYO in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INO-5401+ INO-9012 + LIBTAYO development?
• What are the key designations that have been granted to INO-5401+ INO-9012 + LIBTAYO for GBM?
• What is the forecasted market scenario of INO-5401+ INO-9012 + LIBTAYO for GBM?
• What are the forecasted sales of INO-5401+ INO-9012 + LIBTAYO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to INO-5401+ INO-9012 + LIBTAYO for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

This product will be delivered within 2 business days.